These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 30152527)

  • 81. Pharmacodynamic Activity of the Novel Neurokinin-3 Receptor Antagonist SJX-653 in Healthy Men.
    Anderson RA; Cormier J; Thieroff-Ekerdt R; Boyce M; van den Berg F; Grau D; Turnquist D; Corzo D; Graham P
    J Clin Endocrinol Metab; 2020 Dec; 105(12):e4857-65. PubMed ID: 32946574
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses.
    Fujita T; Matsumoto Y; Kimura T; Yokota S; Sawada M; Majima M; Ohtani Y; Kumagai Y
    Br J Clin Pharmacol; 2002 Sep; 54(3):283-94. PubMed ID: 12236849
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects.
    Sidharta PN; van Giersbergen PL; Dingemanse J
    J Clin Pharmacol; 2013 Nov; 53(11):1131-8. PubMed ID: 23900878
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Population Pharmacokinetic Modeling of JNJ-53718678, a Novel Fusion Inhibitor for the Treatment of Respiratory Syncytial Virus: Results from a Phase I, Double-Blind, Randomized, Placebo-Controlled First-in-Human Study in Healthy Adult Subjects.
    Huntjens DRH; Ouwerkerk-Mahadevan S; Brochot A; Rusch S; Stevens M; Verloes R
    Clin Pharmacokinet; 2017 Nov; 56(11):1331-1342. PubMed ID: 28238203
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Tolerability and Pharmacokinetics of Contezolid at Therapeutic and Supratherapeutic Doses in Healthy Chinese Subjects, and Assessment of Contezolid Dosing Regimens Based on Pharmacokinetic/Pharmacodynamic Analysis.
    Wu J; Wu H; Wang Y; Chen Y; Guo B; Cao G; Wu X; Yu J; Wu J; Zhu D; Guo Y; Yuan H; Hu F; Zhang J
    Clin Ther; 2019 Jun; 41(6):1164-1174.e4. PubMed ID: 31126694
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Toreforant, A Histamine H4 Receptor Antagonist, in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results of 2 Phase II Studies.
    Thurmond RL; Greenspan A; Radziszewski W; Xu XL; Miao Y; Chen B; Ge T; Zhou B; Baker DG; Pavlova D; Ritchlin CT; Tanaka Y; Takeuchi T; Smolen JS
    J Rheumatol; 2016 Sep; 43(9):1637-42. PubMed ID: 27422891
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration.
    Muehlan C; Brooks S; Zuiker R; van Gerven J; Dingemanse J
    Eur Neuropsychopharmacol; 2019 Jul; 29(7):847-857. PubMed ID: 31221502
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Safety, tolerability and pharmacokinetics of trimebutine 3-thiocarbamoylbenzenesulfonate (GIC-1001) in a randomized phase I integrated design study: single and multiple ascending doses and effect of food in healthy volunteers.
    Paquette JM; Rufiange M; Iovu Niculita M; Massicotte J; Lefebvre M; Colin P; Telmat A; Ranger M
    Clin Ther; 2014 Nov; 36(11):1650-64. PubMed ID: 25224876
    [TBL] [Abstract][Full Text] [Related]  

  • 89. First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-962212, a direct, reversible, small molecule factor XIa inhibitor in non-Japanese and Japanese healthy subjects.
    Perera V; Luettgen JM; Wang Z; Frost CE; Yones C; Russo C; Lee J; Zhao Y; LaCreta FP; Ma X; Knabb RM; Seiffert D; DeSouza M; Mugnier P; Cirincione B; Ueno T; Frost RJA
    Br J Clin Pharmacol; 2018 May; 84(5):876-887. PubMed ID: 29346838
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers.
    Lasseter K; Dilzer S; Jansat JM; Garcia Gil E; Caracta CF; Ortiz S
    Pulm Pharmacol Ther; 2012 Apr; 25(2):193-9. PubMed ID: 22366196
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Safety, Tolerability and Pharmacokinetics of FAAH Inhibitor V158866: A Double-Blind, Randomised, Placebo-Controlled Phase I Study in Healthy Volunteers.
    Pawsey S; Wood M; Browne H; Donaldson K; Christie M; Warrington S
    Drugs R D; 2016 Jun; 16(2):181-91. PubMed ID: 26987975
    [TBL] [Abstract][Full Text] [Related]  

  • 92. A multiple-dose double-blind randomized study to evaluate the safety, pharmacokinetics, pharmacodynamics and analgesic efficacy of the TRPV1 antagonist JNJ-39439335 (mavatrep).
    Manitpisitkul P; Flores CM; Moyer JA; Romano G; Shalayda K; Tatikola K; Hutchison JS; Mayorga AJ
    Scand J Pain; 2018 Apr; 18(2):151-164. PubMed ID: 29794306
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Pharmacokinetics and C-reactive protein modelling of anti-interleukin-6 antibody (PF-04236921) in healthy volunteers and patients with autoimmune disease.
    Li C; Shoji S; Beebe J
    Br J Clin Pharmacol; 2018 Sep; 84(9):2059-2074. PubMed ID: 29776017
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects.
    Kato M; Furuie H; Shimizu T; Miyazaki A; Kobayashi F; Ishizuka H
    Br J Clin Pharmacol; 2018 Aug; 84(8):1821-1829. PubMed ID: 29688582
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Safety, tolerability and pharmacokinetics of single and multiple doses of a novel sigma-1 receptor antagonist in three randomized phase I studies.
    Abadias M; Escriche M; Vaqué A; Sust M; Encina G
    Br J Clin Pharmacol; 2013 Jan; 75(1):103-17. PubMed ID: 22607269
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Safety, Pharmacokinetic, and Pharmacodynamic Evaluation After Single and Multiple Ascending Doses of a Novel Selective Androgen Receptor Modulator in Healthy Subjects.
    Bhattacharya I; Tarabar S; Liang Y; Pradhan V; Owens J; Oemar B
    Clin Ther; 2016 Jun; 38(6):1401-1416. PubMed ID: 27085586
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Phase I studies of the safety, tolerability, pharmacokinetics, and pharmacodynamics of DS-1211, a tissue-nonspecific alkaline phosphatase inhibitor.
    Maruyama S; Visser H; Ito T; Limsakun T; Zahir H; Ford D; Tao B; Zamora CA; Stark JG; Chou HS
    Clin Transl Sci; 2022 Apr; 15(4):967-980. PubMed ID: 35021269
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Pharmacokinetic-pharmacodynamic relationships of central nervous system effects of scopolamine in healthy subjects.
    Liem-Moolenaar M; de Boer P; Timmers M; Schoemaker RC; van Hasselt JG; Schmidt S; van Gerven JM
    Br J Clin Pharmacol; 2011 Jun; 71(6):886-98. PubMed ID: 21306419
    [TBL] [Abstract][Full Text] [Related]  

  • 99. A Multipurpose First-in-Human Study With the Novel CXCR7 Antagonist ACT-1004-1239 Using CXCL12 Plasma Concentrations as Target Engagement Biomarker.
    Huynh C; Henrich A; Strasser DS; Boof ML; Al-Ibrahim M; Meyer Zu Schwabedissen HE; Dingemanse J; Ufer M
    Clin Pharmacol Ther; 2021 Jun; 109(6):1648-1659. PubMed ID: 33406277
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS-986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo-controlled trial in healthy participants.
    Catlett IM; Nowak M; Kundu S; Zheng N; Liu A; He B; Girgis IG; Grasela DM
    Br J Clin Pharmacol; 2020 Sep; 86(9):1849-1859. PubMed ID: 32198939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.